Global Inhalation CDMO Market Analysis and Forecast 2025-2031

Summary

According to APO Research, The global Inhalation CDMO market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Inhalation CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Inhalation CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Inhalation CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Inhalation CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Inhalation CDMO include Aptar Pharma, Bend Bioscience, Bespak, Catalent, CritiTech, Enteris Biopharma, Experic, HCmed and Hovione, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Inhalation CDMO, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Inhalation CDMO, also provides the revenue of main regions and countries. Of the upcoming market potential for Inhalation CDMO, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Inhalation CDMO revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Inhalation CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Inhalation CDMO revenue, projected growth trends, production technology, application and end-user industry.


Inhalation CDMO Segment by Company

Aptar Pharma
Bend Bioscience
Bespak
Catalent
CritiTech
Enteris Biopharma
Experic
HCmed
Hovione
Iconovo
Kindeva
Lonza
Particle Sciences
Proveris
Recipharm
Renejix
Ritedose
Vectura
Sanner

Inhalation CDMO Segment by Type

Soft Mist Inhalers (SMIs)
Dry Powder Inhalers (DPIs)
Metered Dose Inhalers (MDIs)
Others

Inhalation CDMO Segment by Application

Commercial
Academic Research
Others

Inhalation CDMO Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inhalation CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Inhalation CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inhalation CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Inhalation CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Inhalation CDMO company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Inhalation CDMO revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview
1.1 Product Definition
1.2 Inhalation CDMO Market by Type
1.2.1 Global Inhalation CDMO Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Soft Mist Inhalers (SMIs)
1.2.3 Dry Powder Inhalers (DPIs)
1.2.4 Metered Dose Inhalers (MDIs)
1.2.5 Others
1.3 Inhalation CDMO Market by Application
1.3.1 Global Inhalation CDMO Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Commercial
1.3.3 Academic Research
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Inhalation CDMO Market Dynamics
2.1 Inhalation CDMO Industry Trends
2.2 Inhalation CDMO Industry Drivers
2.3 Inhalation CDMO Industry Opportunities and Challenges
2.4 Inhalation CDMO Industry Restraints
3 Global Growth Perspective
3.1 Global Inhalation CDMO Market Perspective (2020-2031)
3.2 Global Inhalation CDMO Growth Trends by Region
3.2.1 Global Inhalation CDMO Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Inhalation CDMO Market Size by Region (2020-2025)
3.2.3 Global Inhalation CDMO Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Inhalation CDMO Revenue by Players
4.1.1 Global Inhalation CDMO Revenue by Players (2020-2025)
4.1.2 Global Inhalation CDMO Revenue Market Share by Players (2020-2025)
4.1.3 Global Inhalation CDMO Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Inhalation CDMO Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Inhalation CDMO Key Players Headquarters & Area Served
4.4 Global Inhalation CDMO Players, Product Type & Application
4.5 Global Inhalation CDMO Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Inhalation CDMO Market CR5 and HHI
4.6.3 2024 Inhalation CDMO Tier 1, Tier 2, and Tier 3
5 Inhalation CDMO Market Size by Type
5.1 Global Inhalation CDMO Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Inhalation CDMO Revenue by Type (2020-2031)
5.3 Global Inhalation CDMO Revenue Market Share by Type (2020-2031)
6 Inhalation CDMO Market Size by Application
6.1 Global Inhalation CDMO Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Inhalation CDMO Revenue by Application (2020-2031)
6.3 Global Inhalation CDMO Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Aptar Pharma
7.1.1 Aptar Pharma Comapny Information
7.1.2 Aptar Pharma Business Overview
7.1.3 Aptar Pharma Inhalation CDMO Revenue and Gross Margin (2020-2025)
7.1.4 Aptar Pharma Inhalation CDMO Product Portfolio
7.1.5 Aptar Pharma Recent Developments
7.2 Bend Bioscience
7.2.1 Bend Bioscience Comapny Information
7.2.2 Bend Bioscience Business Overview
7.2.3 Bend Bioscience Inhalation CDMO Revenue and Gross Margin (2020-2025)
7.2.4 Bend Bioscience Inhalation CDMO Product Portfolio
7.2.5 Bend Bioscience Recent Developments
7.3 Bespak
7.3.1 Bespak Comapny Information
7.3.2 Bespak Business Overview
7.3.3 Bespak Inhalation CDMO Revenue and Gross Margin (2020-2025)
7.3.4 Bespak Inhalation CDMO Product Portfolio
7.3.5 Bespak Recent Developments
7.4 Catalent
7.4.1 Catalent Comapny Information
7.4.2 Catalent Business Overview
7.4.3 Catalent Inhalation CDMO Revenue and Gross Margin (2020-2025)
7.4.4 Catalent Inhalation CDMO Product Portfolio
7.4.5 Catalent Recent Developments
7.5 CritiTech
7.5.1 CritiTech Comapny Information
7.5.2 CritiTech Business Overview
7.5.3 CritiTech Inhalation CDMO Revenue and Gross Margin (2020-2025)
7.5.4 CritiTech Inhalation CDMO Product Portfolio
7.5.5 CritiTech Recent Developments
7.6 Enteris Biopharma
7.6.1 Enteris Biopharma Comapny Information
7.6.2 Enteris Biopharma Business Overview
7.6.3 Enteris Biopharma Inhalation CDMO Revenue and Gross Margin (2020-2025)
7.6.4 Enteris Biopharma Inhalation CDMO Product Portfolio
7.6.5 Enteris Biopharma Recent Developments
7.7 Experic
7.7.1 Experic Comapny Information
7.7.2 Experic Business Overview
7.7.3 Experic Inhalation CDMO Revenue and Gross Margin (2020-2025)
7.7.4 Experic Inhalation CDMO Product Portfolio
7.7.5 Experic Recent Developments
7.8 HCmed
7.8.1 HCmed Comapny Information
7.8.2 HCmed Business Overview
7.8.3 HCmed Inhalation CDMO Revenue and Gross Margin (2020-2025)
7.8.4 HCmed Inhalation CDMO Product Portfolio
7.8.5 HCmed Recent Developments
7.9 Hovione
7.9.1 Hovione Comapny Information
7.9.2 Hovione Business Overview
7.9.3 Hovione Inhalation CDMO Revenue and Gross Margin (2020-2025)
7.9.4 Hovione Inhalation CDMO Product Portfolio
7.9.5 Hovione Recent Developments
7.10 Iconovo
7.10.1 Iconovo Comapny Information
7.10.2 Iconovo Business Overview
7.10.3 Iconovo Inhalation CDMO Revenue and Gross Margin (2020-2025)
7.10.4 Iconovo Inhalation CDMO Product Portfolio
7.10.5 Iconovo Recent Developments
7.11 Kindeva
7.11.1 Kindeva Comapny Information
7.11.2 Kindeva Business Overview
7.11.3 Kindeva Inhalation CDMO Revenue and Gross Margin (2020-2025)
7.11.4 Kindeva Inhalation CDMO Product Portfolio
7.11.5 Kindeva Recent Developments
7.12 Lonza
7.12.1 Lonza Comapny Information
7.12.2 Lonza Business Overview
7.12.3 Lonza Inhalation CDMO Revenue and Gross Margin (2020-2025)
7.12.4 Lonza Inhalation CDMO Product Portfolio
7.12.5 Lonza Recent Developments
7.13 Particle Sciences
7.13.1 Particle Sciences Comapny Information
7.13.2 Particle Sciences Business Overview
7.13.3 Particle Sciences Inhalation CDMO Revenue and Gross Margin (2020-2025)
7.13.4 Particle Sciences Inhalation CDMO Product Portfolio
7.13.5 Particle Sciences Recent Developments
7.14 Proveris
7.14.1 Proveris Comapny Information
7.14.2 Proveris Business Overview
7.14.3 Proveris Inhalation CDMO Revenue and Gross Margin (2020-2025)
7.14.4 Proveris Inhalation CDMO Product Portfolio
7.14.5 Proveris Recent Developments
7.15 Recipharm
7.15.1 Recipharm Comapny Information
7.15.2 Recipharm Business Overview
7.15.3 Recipharm Inhalation CDMO Revenue and Gross Margin (2020-2025)
7.15.4 Recipharm Inhalation CDMO Product Portfolio
7.15.5 Recipharm Recent Developments
7.16 Renejix
7.16.1 Renejix Comapny Information
7.16.2 Renejix Business Overview
7.16.3 Renejix Inhalation CDMO Revenue and Gross Margin (2020-2025)
7.16.4 Renejix Inhalation CDMO Product Portfolio
7.16.5 Renejix Recent Developments
7.17 Ritedose
7.17.1 Ritedose Comapny Information
7.17.2 Ritedose Business Overview
7.17.3 Ritedose Inhalation CDMO Revenue and Gross Margin (2020-2025)
7.17.4 Ritedose Inhalation CDMO Product Portfolio
7.17.5 Ritedose Recent Developments
7.18 Vectura
7.18.1 Vectura Comapny Information
7.18.2 Vectura Business Overview
7.18.3 Vectura Inhalation CDMO Revenue and Gross Margin (2020-2025)
7.18.4 Vectura Inhalation CDMO Product Portfolio
7.18.5 Vectura Recent Developments
7.19 Sanner
7.19.1 Sanner Comapny Information
7.19.2 Sanner Business Overview
7.19.3 Sanner Inhalation CDMO Revenue and Gross Margin (2020-2025)
7.19.4 Sanner Inhalation CDMO Product Portfolio
7.19.5 Sanner Recent Developments
8 North America
8.1 North America Inhalation CDMO Revenue (2020-2031)
8.2 North America Inhalation CDMO Revenue by Type (2020-2031)
8.2.1 North America Inhalation CDMO Revenue by Type (2020-2025)
8.2.2 North America Inhalation CDMO Revenue by Type (2026-2031)
8.3 North America Inhalation CDMO Revenue Share by Type (2020-2031)
8.4 North America Inhalation CDMO Revenue by Application (2020-2031)
8.4.1 North America Inhalation CDMO Revenue by Application (2020-2025)
8.4.2 North America Inhalation CDMO Revenue by Application (2026-2031)
8.5 North America Inhalation CDMO Revenue Share by Application (2020-2031)
8.6 North America Inhalation CDMO Revenue by Country
8.6.1 North America Inhalation CDMO Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Inhalation CDMO Revenue by Country (2020-2025)
8.6.3 North America Inhalation CDMO Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
8.6.6 Mexico
9 Europe
9.1 Europe Inhalation CDMO Revenue (2020-2031)
9.2 Europe Inhalation CDMO Revenue by Type (2020-2031)
9.2.1 Europe Inhalation CDMO Revenue by Type (2020-2025)
9.2.2 Europe Inhalation CDMO Revenue by Type (2026-2031)
9.3 Europe Inhalation CDMO Revenue Share by Type (2020-2031)
9.4 Europe Inhalation CDMO Revenue by Application (2020-2031)
9.4.1 Europe Inhalation CDMO Revenue by Application (2020-2025)
9.4.2 Europe Inhalation CDMO Revenue by Application (2026-2031)
9.5 Europe Inhalation CDMO Revenue Share by Application (2020-2031)
9.6 Europe Inhalation CDMO Revenue by Country
9.6.1 Europe Inhalation CDMO Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Inhalation CDMO Revenue by Country (2020-2025)
9.6.3 Europe Inhalation CDMO Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
9.6.9 Spain
9.6.10 Netherlands
9.6.11 Switzerland
9.6.12 Sweden
9.6.13 Poland
10 China
10.1 China Inhalation CDMO Revenue (2020-2031)
10.2 China Inhalation CDMO Revenue by Type (2020-2031)
10.2.1 China Inhalation CDMO Revenue by Type (2020-2025)
10.2.2 China Inhalation CDMO Revenue by Type (2026-2031)
10.3 China Inhalation CDMO Revenue Share by Type (2020-2031)
10.4 China Inhalation CDMO Revenue by Application (2020-2031)
10.4.1 China Inhalation CDMO Revenue by Application (2020-2025)
10.4.2 China Inhalation CDMO Revenue by Application (2026-2031)
10.5 China Inhalation CDMO Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Inhalation CDMO Revenue (2020-2031)
11.2 Asia Inhalation CDMO Revenue by Type (2020-2031)
11.2.1 Asia Inhalation CDMO Revenue by Type (2020-2025)
11.2.2 Asia Inhalation CDMO Revenue by Type (2026-2031)
11.3 Asia Inhalation CDMO Revenue Share by Type (2020-2031)
11.4 Asia Inhalation CDMO Revenue by Application (2020-2031)
11.4.1 Asia Inhalation CDMO Revenue by Application (2020-2025)
11.4.2 Asia Inhalation CDMO Revenue by Application (2026-2031)
11.5 Asia Inhalation CDMO Revenue Share by Application (2020-2031)
11.6 Asia Inhalation CDMO Revenue by Country
11.6.1 Asia Inhalation CDMO Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Inhalation CDMO Revenue by Country (2020-2025)
11.6.3 Asia Inhalation CDMO Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Inhalation CDMO Revenue (2020-2031)
12.2 SAMEA Inhalation CDMO Revenue by Type (2020-2031)
12.2.1 SAMEA Inhalation CDMO Revenue by Type (2020-2025)
12.2.2 SAMEA Inhalation CDMO Revenue by Type (2026-2031)
12.3 SAMEA Inhalation CDMO Revenue Share by Type (2020-2031)
12.4 SAMEA Inhalation CDMO Revenue by Application (2020-2031)
12.4.1 SAMEA Inhalation CDMO Revenue by Application (2020-2025)
12.4.2 SAMEA Inhalation CDMO Revenue by Application (2026-2031)
12.5 SAMEA Inhalation CDMO Revenue Share by Application (2020-2031)
12.6 SAMEA Inhalation CDMO Revenue by Country
12.6.1 SAMEA Inhalation CDMO Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Inhalation CDMO Revenue by Country (2020-2025)
12.6.3 SAMEA Inhalation CDMO Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings